Physician profile
Joann O Rivera
NPI 1871556266
$3,634.52
in general payments reported to CMS, 2019-2025
28 companies · $995 in 2025
The $995 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.93 · 2022: $432 · 2023: $680 · 2024: $1,492 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,094.01 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $535.85 | 2019-2025 | Vraylar, Linzess, Avycaz |
| Lilly USA, LLC | $376.05 | 2022-2025 | Jardiance, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $316.92 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $212.37 | 2023-2024 | Spravato |
| Amgen INC. | $170.92 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $150.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $132.55 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $73.49 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $64.24 | 2025 | Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.45 | 2023-2024 | Xifaxan, Trulance |
| Hologic Sales and Service, LLC | $46.16 | 2024 | Aptima, Thinprep 2000 Processor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.84 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $35.37 | 2025 | Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $29.55 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.49 | 2025 | Caplyta |
| Seqirus USA INC | $27.99 | 2022-2025 | Flucelvax, Fluad |
| Abiomed | $27.73 | 2024 | Impella |
| Baxter Healthcare | $27.08 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.94 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.79 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $22.45 | 2025 | Keveyis |
| Vbi Vaccine (Delaware) INC. | $22.07 | 2022 | |
| Merck Sharp & Dohme LLC | $20.04 | 2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $19.48 | 2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $18.04 | 2025 | Doc Band |
| Grifols USA, LLC | $15.47 | 2023 | Prolastin-C Liquid |
| Corium, LLC | $15.16 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.